查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1692168

湿疹治疗市场 - 全球产业规模、份额、趋势、机会和预测，按治疗、配销通路、地区和竞争细分，2020-2030 年预测

Eczema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Distribution Channel, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球湿疹治疗市场价值为 132.5 亿美元，预计在预测期内将实现令人瞩目的成长，到 2030 年的复合年增长率为 7.46%。全球湿疹治疗市场是指致力于治疗湿疹的製药和医疗保健行业，湿疹是一种以发炎、搔痒和发红为特征的慢性皮肤病。该市场涵盖各种产品，包括外用药膏、软膏、口服药物和生物製剂，旨在缓解湿疹症状和控制病情。根据美国国家湿疹协会估计，3,160 万美国人患有湿疹，而且由于污染、生活方式的改变和化学物质的接触，湿疹病例预计还会增加。湿疹盛行率的不断上升推动了对有效治疗的需求，促进了湿疹治疗市场的扩张。随着越来越多的人寻求缓解，製药公司正在投资创新解决方案来治疗这种慢性皮肤病。

市场概况
预测期 2026-2030
2024 年市场规模 132.5 亿美元
2030 年市场规模 202.4 亿美元
2025-2030 年复合年增长率 7.46％
成长最快的领域 网路药局
最大的市场 北美洲

主要市场驱动因素

湿疹盛行率上升

主要市场挑战

多元化的患者群体

主要市场趋势

生物疗法带来治疗革命

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球湿疹治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗（抗生素、抗组织胺、钙调磷酸酶抑制剂、皮质类固醇、润肤剂和保湿剂、免疫调节剂、白血球介素抑制剂）
    • 按配销通路（医院和诊所、网路药局、零售药局）
    • 按地区
    • 按公司分类（2024）
  • 市场地图
    • 按治疗
    • 按配销通路
    • 按地区

第 6 章：北美湿疹治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 加拿大
    • 墨西哥

第 7 章：欧洲湿疹治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区湿疹治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲湿疹治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲湿疹治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 科威特

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 合併与收购
  • 产品发布

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章：竞争格局

    • 赛诺菲公司
      • 业务概览
      • 产品供应
      • 最新动态
      • 财务状况（据报告）
      • 主要人员
      • SWOT 分析
    • Encore 皮肤科公司
    • 艾伯维公司
    • F 霍夫曼-拉罗氏公司
    • 诺华公司
    • 再生元製药公司
    • 安斯泰来製药公司
    • 葛兰素史克公司
    • 阿斯特捷利康公司
    • 辉瑞公司

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 18752

Global Eczema Therapeutics Market was valued at USD 13.25 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.46% through 2030. The Global Eczema Therapeutics Market refers to the pharmaceutical and healthcare sector dedicated to treating eczema, a chronic skin condition characterized by inflammation, itching, and redness. This market encompasses various products, including topical creams, ointments, oral medications, and biologics, designed to alleviate eczema symptoms and manage the condition. According to the National Eczema Association estimates that 31.6 million Americans have eczema, with cases expected to rise due to pollution, lifestyle changes, and chemical exposure. This growing prevalence is driving demand for effective treatments, fueling the expansion of the eczema therapeutics market. As more people seek relief, pharmaceutical companies are investing in innovative solutions to address this chronic skin condition.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 13.25 Billion
Market Size 2030USD 20.24 Billion
CAGR 2025-20307.46%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Eczema

The most apparent way in which the rising prevalence of eczema boosts the growth of the eczema therapeutics market is through the expanding patient population. Eczema affects people of all ages, from infants to adults, and its incidence has been steadily climbing. This larger pool of potential patients translates into a growing demand for effective treatments, thereby driving market growth. For instance, according to the National Eczema Association reports that eczema affects over 30 million Americans, with a prevalence of 10%-20% in children and 2%-5% in adults, highlighting its widespread impact and the need for effective treatments across different age groups.

As eczema continues to affect a greater number of individuals and families, awareness of the condition has risen significantly. Patients and their caregivers are increasingly seeking medical advice and treatment options. This growing awareness contributes to early diagnosis and intervention, fostering the adoption of eczema therapeutics and driving market expansion.

Eczema is a chronic condition that can significantly impact a person's quality of life. The constant itching, discomfort, and the potential for skin infections drive individuals to seek solutions that provide relief and long-term management. This demand for effective treatments encourages pharmaceutical companies and researchers to invest in the development of innovative therapies.

Key Market Challenges

Diverse Patient Population

One of the primary challenges faced by the eczema therapeutics market is the diverse nature of the patient population. Eczema can manifest differently in individuals, with varying triggers and severity levels. Tailoring treatments to the specific needs of each patient can be complex and requires a personalized approach. Pharmaceutical companies are increasingly investing in research to address this challenge by developing more targeted therapies.

Key Market Trends

Biologic Therapies Revolutionizing Treatment

Biologic drugs have already made a significant impact on the eczema therapeutics market, but their potential is far from exhausted. In the coming years, we can expect to see the development of more targeted and efficient biologics that offer even better results with fewer side effects. These innovative therapies are likely to become more accessible to a broader range of eczema patients.

Key Market Players

  • Sanofi SA
  • Encore Dermatology Inc.
  • AbbVie Inc.
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • GSK PLC
  • AstraZeneca PLC
  • Pfizer Inc.

Report Scope:

In this report, the Global Eczema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Eczema Therapeutics Market, By Treatment:

  • Antibiotics
  • Antihistamines
  • Calcineurin Inhibitors
  • Corticosteroids
  • Emollients & Moisturizers
  • Immunomodulators
  • Interleukin Inhibitors

Eczema Therapeutics Market, By Distribution Channel:

  • Hospital & Clinics
  • Online Pharmacies
  • Retail Pharmacies

Eczema Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Eczema Therapeutics Market.

Available Customizations:

Global Eczema Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Eczema Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 5.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map
    • 5.3.1. By Treatment
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Eczema Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 6.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Eczema Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Eczema Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Eczema Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Distribution Channel

7. Europe Eczema Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 7.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Eczema Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. United Kingdom Eczema Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. France Eczema Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Eczema Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Eczema Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Distribution Channel

8. Asia-Pacific Eczema Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 8.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Eczema Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Japan Eczema Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. India Eczema Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. Australia Eczema Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. South Korea Eczema Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Distribution Channel

9. South America Eczema Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 9.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Eczema Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Eczema Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Eczema Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Eczema Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
    • 10.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Eczema Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Eczema Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Eczema Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Distribution Channel
    • 10.3.4. Kuwait Eczema Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Treatment
        • 10.3.4.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

    • 14.6.1. Sanofi SA
      • 14.6.1.1. Business Overview
      • 14.6.1.2. Product Offerings
      • 14.6.1.3. Recent Developments
      • 14.6.1.4. Financials (As Reported)
      • 14.6.1.5. Key Personnel
      • 14.6.1.6. SWOT Analysis
    • 14.6.2. Encore Dermatology Inc
    • 14.6.3. AbbVie Inc
    • 14.6.4. F Hoffmann-La Roche AG
    • 14.6.5. Novartis AG
    • 14.6.6. Regeneron Pharmaceuticals Inc
    • 14.6.7. Astellas Pharma Inc
    • 14.6.8. GSK PLC
    • 14.6.9. AstraZeneca PLC
    • 14.6.10. Pfizer Inc

15. Strategic Recommendations

16. About Us & Disclaimer